Microdosers report significantly lower levels of anxiety and depression than non-microdosers, highlighting potential therapeutic effects.
The analysis involves self-reported health-related motivations for microdosing, indicating that mental wellness is a priority for participants.
Assessment of psychological outcomes reveals a notable correlation between microdosing and improved mental health metrics over time.
Potential mental health benefits may indicate the therapeutic use of psychedelics, emphasizing the need for further investigation on long-term effects.